42 related articles for article (PubMed ID: 28492441)
1. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial.
Henshaw DS; Edwards CJ; Dobson SW; Jaffe D; Turner JD; Reynolds JW; Thompson GR; Russell G; Weller R
Reg Anesth Pain Med; 2024 Feb; 49(2):94-101. PubMed ID: 37280083
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients.
Melek M; Ari H; Ari S; Cilgin MC; Yarar M; Huysal K; Ağca FV; Bozat T
Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3221-3232. PubMed ID: 37209152
[TBL] [Abstract][Full Text] [Related]
3. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Schwenk ES; Viscusi ER; Buvanendran A; Hurley RW; Wasan AD; Narouze S; Bhatia A; Davis FN; Hooten WM; Cohen SP
Reg Anesth Pain Med; 2018 Jul; 43(5):456-466. PubMed ID: 29870457
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic range anti-factor Xa activity 24 hours after subcutaneous injection of 40 mg of enoxaparin in a patient with an epidural catheter in situ.
Czempik PF
Anaesthesiol Intensive Ther; 2024; 56(1):86-88. PubMed ID: 38741449
[No Abstract] [Full Text] [Related]
5. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: an infographic.
Henshaw DS; Schwenk ES; Gupta RK
Reg Anesth Pain Med; 2024 Feb; 49(2):102-103. PubMed ID: 37591616
[No Abstract] [Full Text] [Related]
6. Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series.
Pannucci CJ; Varghese TK; Graves KK; Prazak AM
Int J Surg Case Rep; 2016; 28():114-116. PubMed ID: 27693871
[TBL] [Abstract][Full Text] [Related]
7. Peak plasma anti-Xa direct oral anticoagulant levels after gastrointestinal surgeries: A retrospective cohort.
Huroy M; Selby R; Sutradhar S; Galanaud JP; Abdulrehman J
Thromb Res; 2024 Jun; 238():85-87. PubMed ID: 38692087
[No Abstract] [Full Text] [Related]
8. Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review of Spinal Epidural Hematoma.
Leffert LR; Dubois HM; Butwick AJ; Carvalho B; Houle TT; Landau R
Anesth Analg; 2017 Jul; 125(1):223-231. PubMed ID: 28628578
[TBL] [Abstract][Full Text] [Related]
9. PERIPHERAL NERVE BLOCKS IN PATIENTS ON ANTITHROMBOTIC DRUGS - A RESCUE OR AN UNNECESSARY RISK?
Poredoš P
Acta Clin Croat; 2022 Sep; 61(Suppl 2):67-77. PubMed ID: 36824631
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB
JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389
[TBL] [Abstract][Full Text] [Related]
11. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
May CC; Cua S; Smetana KS; Powers CJ
World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
[TBL] [Abstract][Full Text] [Related]
12. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.
Narouze S; Benzon HT; Provenzano D; Buvanendran A; De Andres J; Deer T; Rauck R; Huntoon MA
Reg Anesth Pain Med; 2018 Apr; 43(3):225-262. PubMed ID: 29278603
[TBL] [Abstract][Full Text] [Related]
13. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Cohen SP; Bhatia A; Buvanendran A; Schwenk ES; Wasan AD; Hurley RW; Viscusi ER; Narouze S; Davis FN; Ritchie EC; Lubenow TR; Hooten WM
Reg Anesth Pain Med; 2018 Jul; 43(5):521-546. PubMed ID: 29870458
[TBL] [Abstract][Full Text] [Related]
14. Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines.
Henshaw DS; Turner JD; Forest DJ; Thompson GR; Weller RS
Reg Anesth Pain Med; 2017; 42(4):432-436. PubMed ID: 28492441
[TBL] [Abstract][Full Text] [Related]
15. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
